// App-Quantinova.ai

70 : A Phase 1/2 Study Of Blinatumomab In Pediatric Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

Researchers

Presenter

  • Arend von Stackelberg

Principal Investigators

  • Rupert Handgretinger

  • Steven G. DuBois

  • Maureen M. -Brien

  • Christian M. Zwaan

  • Chris Holland

  • Noemi Mergen

  • Anja Fischer

  • Min Zhu

  • Youssef Hijazi

  • James Whitlock

  • Lia Gore

  • Franco Locatelli

  • Carmelo Rizzari

  • Tanya M. Trippett

  • Arndt Borkhardt

  • Susan R. Rheingold

  • Peter Bader

  • Deepa Bhojwani

  • Todd M. Cooper

Medical Centers

  • Children's Healthcare of Atlanta, Atlanta, GA

  • Department of General Pediatrics, Hematology/Oncology, University Childrens Hospital, Tuebingen, Germany

  • Divison of Stem Cell Transplanation and Immunology, Hospital of Children and Adolescent of Frankfurt, Frankfurt, Germany

  • Epidemiology and Biostatistics, University of California San Francisco School of Medicine, San Francisco, CA

  • Hospital for Sick Children, Toronto, ON, Canada

  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH

  • Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN

  • Department of Pediatric Oncology/Hematology, Charite Campus Virchow, Berlin, Germany

  • Clinica Pediatrica, Universit degli studi di Milano-Bicocca, Fondazione MBBM/Ospedale S. Gerardo, Monza, Italy

  • Children's Hospital Colorado, Aurora, CO

  • Pediatrics, Erasmus Medical Centre - Sophia Childrens Hospital, Rotterdam, Netherlands

  • Institute of Neuropathology, University of Duesseldorf, Duesseldorf, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • University of Pavia, Pavia, Italy

Locations

  • Canada

  • Italy

  • Netherlands

  • Germany

  • United States

Companies

  • Amgen Inc.

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Acute lymphoblastic leukemia

  • Cytokine release syndrome

  • Hypertension

  • Epilepsy

  • Anemia

Biomarkers

  • Interferon-gamma

  • Interleukin 10

  • Interleukin 6

  • Interleukin-2

  • Tumor necrosis factor

  • Twist-related protein 1

Drug/Treatment

  • Blinatumomab

  • IFN-lambda

  • Interleukin-10

Outcome

  • N/A

Study Design

  • pharmacokinetics

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved